Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children and infants are currently on hold, including two not previously disclosed by Moderna.

Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children and infants are currently on hold, including two not previously disclosed by Moderna.

GSK revises deal with Chongqing Zhifei Biological Products, extending Shingrix distribution rights in China through 2034 but reducing purchase commitment from £2.5B to £2.3B. Agreement now includes potential collaboration for RSV vaccine Arexvy in China, pending approval.

Moderna CEO Stéphane Bancel argued that the drug industry’s efforts to prepare for a future pandemic are part of efforts to protect Americans, defending the sector’s work even as President-elect Donald Trump plans to fill US health agencies with pharma and vaccine critics.

GSK has axed a Phase 2 study of a chronic hepatitis B therapeutic vaccine, adding to a string of treatment R&D hurdles for the liver infection.

Gilead acquires HTI T-cell immunogen HIV vaccines from Barcelona’s Aelix Therapeutics for an undisclosed amount. The vaccines, ChAdOx1.HTI and MVA.HTI, showed promising Phase 2a results when combined with vesatolimod in HIV patients on antiretroviral therapy. The acquisition adds to Gilead’s extensive HIV drug portfolio.